Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916442 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL16283732 | 0.87 | ALDH1A1 (0.62) | ALDH1A1MEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL20665169 | 0.84 | PDK2 (0.52) | SPHK1SPHK2PDK2 | |
| SCHEMBL13777926 | 0.84 | DPP4 (0.59) | ALDH1A1SPHK1SPHK2CA2PDK2 | |
| SCHEMBL4928733 | 0.84 | MMP2 (0.52) | ALDH1A1MEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL4928721 | 0.84 | MMP2 (0.52) | ALDH1A1MEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL95494 | 0.82 | SPHK1 (0.55) | ALDH1A1SPHK1SPHK2CA2PDK2 | |
| SCHEMBL13431541 | 0.82 | HSD11B1 (0.49) | SPHK1SPHK2PDK2DPP4HPGD | |
| SCHEMBL13753547 | 0.81 | HPGD (0.71) | ALDH1A1MEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL11251209 | 0.81 | SPHK2 (0.62) | SPHK1SPHK2CA2PDK2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | claimed |
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | disclosed |
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | ALDH1A1 28/4885MEN1 1562/4885HTT 2317/4885 |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | ALDH1A1 27/4885MEN1 1683/4885HTT 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.